PhRMA Japan Industry Vision Report
Japan’s rapidly aging population and recent changes to the policy
environment have made reforms to the country’s health care system an
urgent issue. This vision paper outlines the constructive role
innovative biopharmaceutical companies can play to ensure new and
innovative medicines continue to be developed and delivered to Japanese
patients in a timely manner.
This patient-centric approach is supported by three key pillars: 1) Advancing innovation, 2) Securing patient access to new innovation in a sustainable universal healthcare system, and 3) Ensuring policy decisions are evidence based.
This patient-centric approach is supported by three key pillars: 1) Advancing innovation, 2) Securing patient access to new innovation in a sustainable universal healthcare system, and 3) Ensuring policy decisions are evidence based.